

## PerCP/Cyanine5.5 anti-mouse CD8a Antibody

<b>Catalog# / Size</b>	100733 / 25 µg 100734 / 100 µg
<b>Clone</b>	53-6.7
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T8, Lyt2, Ly-2
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
<b>Concentration</b>	0.2 mg/mL
<b>Storage &amp; Handling</b>	The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.  * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes <sup>3</sup> . The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a <sup>+</sup> cells. Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1,3</sup> , <i>in vivo</i> and <i>in vitro</i> cell depletion <sup>2,10,15</sup> , inhibition of CD8 T cell proliferation <sup>3</sup> , blocking of cytotoxicity <sup>3,4</sup> , immunohistochemical staining <sup>5,6</sup> of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX) <sup>29,30</sup> . Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or <i>in vivo</i> studies (Cat No. 100746).
<b>Additional Product Notes</b>	BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our

PerCP/Cyanine5.5 products. Contact [Technical Service](#) if you have any questions.

## Application References

(PubMed link indicates  
BioLegend citation)

1. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IHC, IP)
2. Hathcock KS. 1991. *Current Protocols in Immunology*. 3.4.1. (Deplete)
3. Takahashi K, *et al.* 1992. *P. Natl. Acad. Sci. USA* 89:5557. (Block, IP)
4. Ledbetter JA, *et al.* 1981. *J. Exp. Med.* 153:1503. (Block)
5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Kamimura D, *et al.* 2006. *J. Immunol.* 177:306.
9. Bouwer HGA, *et al.* 2006. *P. Natl. Acad. Sci. USA* 103:5102. (FC, Deplete)
10. Kao C, *et al.* 2005. *Int. Immunol.* 17:1607. [PubMed](#)
11. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309. (FC) [PubMed](#)
12. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
13. Lee CH, *et al.* 2009. *Clin. Cancer Res.* [PubMed](#)
14. Geiben-Lynn R, *et al.* 2008. *Blood* 112:4585. (Deplete) [PubMed](#)
15. Kingeter LM, *et al.* 2008. *J. Immunol.* 181:6244. [PubMed](#)
16. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
17. Andrews DM, *et al.* 2008. *J. Virol.* 82:4931. [PubMed](#)
18. Britschqui MR, *et al.* 2008. *J. Immunol.* 181:7681. [PubMed](#)
19. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
20. Jordan JM, *et al.* 2008. *Infect. Immun.* 76:3717. [PubMed](#)
21. Todd DJ, *et al.* 2009. *J. Exp. Med.* 206:2151. [PubMed](#)
22. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
23. Medyouf H, *et al.* 2010. *Blood* 115:1175. [PubMed](#)
24. Riedl P, *et al.* 2009. *J. Immunol.* 183:370. [PubMed](#)
25. Apte SH, *et al.* 2010. *J. Immunol.* 185:998. [PubMed](#)
26. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
27. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
28. Cui L, *et al.* 2015. *J Control Release.* 206:220. [PubMed](#)
29. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
30. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Dai L, *et al.* 2020. *Cell.* 182(3):722-733.e11. [PubMed](#)
2. Xing J, *et al.* 2021. *Cell Reports.* 35(12):109205. [PubMed](#)
3. Schuster M, *et al.* 2017. *J Immunol.* 199:920. [PubMed](#)
4. Yoon J *et al.* 2018. *J Vis Exp.* -141. [PubMed](#)
5. Turecamo SE, *et al.* 2018. *Matrix Biol.* 67:01:00. [PubMed](#)
6. Garber C, *et al.* 2019. *Nat Neurosci.* 1.802777778. [PubMed](#)
7. Wang X, *et al.* 2019. *Cell Res.* 29:787. [PubMed](#)
8. Zheng X, *et al.* 2019. *PLoS Pathog.* 15:e1008036. [PubMed](#)
9. Lang J, *et al.* 2020. *Nat Commun.* 11:1338. [PubMed](#)
10. Hudson WH, *et al.* 2020. *Immunity.* 51(6):1043-1058.e4. [PubMed](#)
11. Zhang H, *et al.* 2021. *Front Immunol.* 12:644520. [PubMed](#)
12. Vella JL, *et al.* 2021. *Life Sci Alliance.* 4. [PubMed](#)
13. Platt DJ, *et al.* 2021. *Cell Reports.* 35(6):109113. [PubMed](#)
14. Gern BH, *et al.* 2021. *Cell Host Microbe.* 29(4):594-606.e6. [PubMed](#)
15. Cornax I, *et al.* 2021. *Microorganisms.* 9:00. [PubMed](#)
16. Zhou J, *et al.* 2019. *Immunity.* 50:403. [PubMed](#)
17. Zhang R, *et al.* 2019. *Cell Rep.* 28:2647. [PubMed](#)
18. Murata A, *et al.* 2020. *Front Immunol.* 11:775. [PubMed](#)
19. Lefebvre MN, *et al.* 2021. *Cell Rep.* 37:109956. [PubMed](#)
20. Kim D, *et al.* 2021. *Nanomicro Lett.* 13:31. [PubMed](#)
21. Barry KC, *et al.* 2018. *Nat Med.* 24:1178. [PubMed](#)
22. Zhang P *et al.* 2019. *Cell Rep.* 27(11):3117-3123. [PubMed](#)
23. Kim CJ, *et al.* 2018. *Immunity.* 49:1034. [PubMed](#)
24. Aldon Y, *et al.* 2020. *J Immunol.* 204:903. [PubMed](#)
25. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 5:64. [PubMed](#)
26. Yang C, *et al.* 2021. *J Immunother Cancer.* 9. [PubMed](#)
27. Sawada J, *et al.* 2021. *Am J Pathol.* 191:396. [PubMed](#)
28. Pack AD, *et al.* 2021. *Cell Reports.* 36(8):109586. [PubMed](#)
29. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
30. Chen L, *et al.* 2020. *Cancer Immunol Res.* 0.457638889. [PubMed](#)
31. Chow MT *et al.* 2019. *Immunity.* 50(6):1498-1512. [PubMed](#)
32. Choi H *et al.* 2019. *Cell Rep.* 27(3):806-819. [PubMed](#)
33. Sultan H, *et al.* 2018. *Cancer Immunol Res.* 6:617. [PubMed](#)
34. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503. [PubMed](#)
35. Alotaibi F, *et al.* 2021. *Front Immunol.* 11:584937. [PubMed](#)
36. Hayatsu N *et al.* 2017. *Immunity.* 47(2):268-283. [PubMed](#)
37. Wu J, *et al.* 2020. *Sci Adv.* 6:eaba3458. [PubMed](#)
38. Hu D, *et al.* 2021. *J Cell Mol Med.* 25:2900. [PubMed](#)
39. Juul-Madsen K, *et al.* 2021. *Proc Natl Acad Sci U S A.* 118. [PubMed](#)
40. Kienzl M, *et al.* 2020. *Oncoimmunology.* 9:1776059. [PubMed](#)
41. Hong JY, *et al.* 2020. *Cell.* 180(5):847-861. [PubMed](#)
42. Xu X, *et al.* 2021. *J Nanobiotechnology.* 19:376. [PubMed](#)
43. Sugita J, *et al.* 2021. *Nat Commun.* 12:1910. [PubMed](#)
44. Paiva RS, *et al.* 2021. *Eur J Immunol.* 51:1968. [PubMed](#)
45. Mizraji\* G, *et al.* 2013. *J Vis Exp.* 77: 50388. [PubMed](#)

46. Collinson-Pautz M, *et al.* 2016. PLoS One. 11:e0164547. [PubMed](#)
47. Dos Santos Dias L, *et al.* 2021. PLoS Pathog. e1009324:17. [PubMed](#)
48. Solanki A, *et al.* 2018. Development. 145. [PubMed](#)
49. Stivala S, *et al.* 2019. J Clin Invest. 130:1596. [PubMed](#)
50. Green DP, *et al.* 2019. Neuron. 101:412. [PubMed](#)
51. Terashima Y, *et al.* 2020. Nat Commun. 11:609. [PubMed](#)
52. Snyder LM, *et al.* 2022. Immunohorizons. 6:660. [PubMed](#)
53. Chen D, *et al.* 2020. Cancer Immunol Res. 8:883. [PubMed](#)
54. Ruhland MK, *et al.* 2020. Cancer Cell. 37(6):786-799.e5. [PubMed](#)
55. Ji B, *et al.* 2016. Cell Death Differ. 23:759-75. [PubMed](#)
56. Holvoet B, *et al.* 2015. Stem Cell Reports. 5: 1183-1195. [PubMed](#)
57. Dekhtiarenko I, *et al.* 2013. J Immunol. 190:3399. [PubMed](#)
58. Chen X *et al.* 2017. Cell stem cell. 21(6):747-760. [PubMed](#)
59. Smith AS, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
60. Agrawal M, *et al.* 2021. Cells. 10:. [PubMed](#)
61. Yin Q, *et al.* 2021. Proc Natl Acad Sci U S A. 118: . [PubMed](#)
62. Hönes J, *et al.* 2017. Sci Rep. . 10.1038/s41598-017-15866-9. [PubMed](#)
63. Xu J *et al.* 2018. Cell. 173(3):762-775. [PubMed](#)
64. Kooreman NG *et al.* 2018. Cell stem cell. 22(4):501-513. [PubMed](#)
65. Ren J, *et al.* 2019. PLoS Biol. 17:e3000270. [PubMed](#)
66. Hildebrand KM, *et al.* 2021. PLoS One. 16:e0253864. [PubMed](#)
67. Shi R, *et al.* 2022. Theranostics. 12:875. [PubMed](#)
68. Weaver JD, *et al.* 2022. Oncoimmunology. 11:2141007. [PubMed](#)
69. Brigas HC, *et al.* 2021. Cell Reports. 36(9):109574. [PubMed](#)
70. Barsoumian HB, *et al.* 2020. J Immunother Cancer. 8:00. [PubMed](#)
71. Pilzecker B, *et al.* 2016. Nucleic Acids Res. 44: 4734 - 4744. [PubMed](#)
72. Niknam S, *et al.* 2018. Clin Cancer Res. 24:5735. [PubMed](#)
73. Novince CM, *et al.* 2017. Sci Rep. 7:5747. [PubMed](#)
74. Place D, *et al.* 2017. PLoS One. 10.1371/journal.pone.0190384. [PubMed](#)
75. Hu Y, *et al.* 2022. J Nanobiotechnology. 20:417. [PubMed](#)
76. Fang E, *et al.* 2022. MedComm (2020). 3:e117. [PubMed](#)
77. Tondini E, *et al.* 2022. NPJ Vaccines. 7:64. [PubMed](#)
78. Brandi P, *et al.* 2022. Cell Rep. 38:110184. [PubMed](#)
79. Chen X, *et al.* 2021. Cell Rep. 37:109991. [PubMed](#)
80. Zuo W, *et al.* 2022. Cell Death Discov. 8:257. [PubMed](#)
81. Zuo S, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
82. Dutow P, *et al.* 2014. J Infect Dis. 209:1269. [PubMed](#)
83. White C, *et al.* 2015. J Immunol. 194:697. [PubMed](#)
84. Uddback I, *et al.* 2016. Sci Rep. 6:20137. [PubMed](#)
85. Chung L *et al.* 2018. Cell host & microbe. 23(2):203-214. [PubMed](#)
86. Kemp V, *et al.* 2018. Cancer Gene Ther. 26:268. [PubMed](#)
87. Wu J *et al.* 2019. Immunity. 50(5):1218-1231. [PubMed](#)
88. Kaur A, *et al.* 2019. Cancer Discov. 9:64. [PubMed](#)
89. Liu W, *et al.* 2021. Cell Death Discov. 7:136. [PubMed](#)
90. Carbone C, *et al.* 2021. J Immunother Cancer. 9:. [PubMed](#)
91. Bourque J, *et al.* 2021. Heliyon. 7:e08311. [PubMed](#)
92. Alameh MG, *et al.* 2021. Immunity. 54:2877. [PubMed](#)
93. Bullard BL, *et al.* 2022. NPJ Vaccines. 7:65. [PubMed](#)
94. Dobson HE, *et al.* 2020. Mucosal Immunol. 0.901388889. [PubMed](#)
95. Parayath NN, *et al.* 2020. Nat Commun. 4.680555556. [PubMed](#)
96. Lee L, *et al.* 2016. PLoS One. 11:e0167693. [PubMed](#)
97. Ying Zhang *et al.* 2017. Cancer cell. 32(3):377-391. [PubMed](#)
98. Karandikar SH, *et al.* 2019. Anal Chem. 91:3405. [PubMed](#)
99. Sun Y, *et al.* 2022. Mol Ther Oncolytics. 25:160. [PubMed](#)
100. Frost JN, *et al.* 2021. Med (N Y). 2:164. [PubMed](#)
101. Ohtsuka J, *et al.* 2021. iScience. Online ahead of print. [PubMed](#)
102. Maulloo CD, *et al.* 2021. Front Immunol. 12:714842. [PubMed](#)
103. Zhao D, *et al.* 2020. Cancer Discov. 10:1374. [PubMed](#)
104. Chandra J, *et al.* 2016. Immunol Cell Biol. 10.1038/icb.2016.83. [PubMed](#)
105. Wang Z *et al.* 2018. Immunity. 49(1):80-92. [PubMed](#)
106. Shi R, *et al.* 2019. J Cancer. 10:367. [PubMed](#)
107. Karandikar SH, *et al.* 2019. JCI Insight. 5. [PubMed](#)
108. Zhang W, *et al.* 2020. Nat Commun. 11:1187. [PubMed](#)
109. Wuggenig P, *et al.* 2020. Commun Biol. 3:130. [PubMed](#)
110. Yu H, *et al.* 2021. Front Oncol. 11:736882. [PubMed](#)
111. Wüthrich M, *et al.* 2021. MBio. 12:e0201821. [PubMed](#)
112. Ryan NM, *et al.* 2022. Front Immunol. 13:932742. [PubMed](#)
113. Kohn EM, *et al.* 2022. J Immunol. 208:1417. [PubMed](#)
114. Desai P, *et al.* 2021. Cell. 184(5):1214-1231.e16. [PubMed](#)
115. Dekhtiarenko I, *et al.* 2016. PLoS Pathog. 12:e1006072. [PubMed](#)
116. Tang Y, *et al.* 2019. Nat Commun. 10:4157. [PubMed](#)
117. Lee SC *et al.* 2018. Cancer cell. 34(2):225-241. [PubMed](#)
118. Matsumura T, *et al.* 2022. Nat Commun. 13:7064. [PubMed](#)
119. Ghorbani S, *et al.* 2022. Nat Commun. 13:2445. [PubMed](#)
120. Yuan M, *et al.* 2022. Oxid Med Cell Longev. 2022:5479491. [PubMed](#)
121. Wang Y, *et al.* 2020. Virol Sin. 36:122. [PubMed](#)
122. Hartwig S, *et al.* 2014. PLoS One. 9:90720. [PubMed](#)
123. Younes AI, *et al.* 2021. Transl Oncol. 14:100983. [PubMed](#)
124. Highton AJ, *et al.* 2019. Wellcome Open Res. 4:78. [PubMed](#)
125. Liu YG, *et al.* 2019. FASEB J. 33:5018. [PubMed](#)

126. Yao C, *et al.* 2018. Autophagy. 1.854861111. [PubMed](#)
127. Li E, *et al.* 2021. Front Immunol. 12:667177. [PubMed](#)
128. Mezzapelle R, *et al.* 2021. EMBO Mol Med. 13:e12344. [PubMed](#)
129. Wang D, *et al.* 2022. EMBO Rep. 23:e53691. [PubMed](#)
130. Unsinger J, *et al.* 2021. J Leukoc Biol. 109:697. [PubMed](#)
131. Jing Y, *et al.* 2021. Front Immunol. 12:651860. [PubMed](#)
132. Woodring T, *et al.* 2022. iScience. 25:104934. [PubMed](#)
133. Pan Y, *et al.* 2021. Br J Pharmacol. 178:4907. [PubMed](#)
134. Okada R, *et al.* 2021. EBioMedicine. 67:103345. [PubMed](#)
135. MaruYama T, *et al.* 2015. J Leukoc Biol. 98: 385-393. [PubMed](#)
136. Muri J, *et al.* 2020. Cell Reports. 29(9):2731-2744.e4. [PubMed](#)
137. Schuster M, *et al.* 2019. Front Immunol. 10:1583. [PubMed](#)
138. Bennion BG, *et al.* 2019. J Virol. 93. [PubMed](#)
139. Contreras NA, *et al.* 2019. PLoS Pathog. 15:e1007890. [PubMed](#)
140. Fan MY *et al.* 2018. Cell reports. 25(5):1204-1213 . [PubMed](#)
141. Zhao N, *et al.* 2018. J Clin Invest. 26:84. [PubMed](#)
142. Shaikh H, *et al.* 2021. Front Immunol. 12:689896. [PubMed](#)
143. Xu Y, *et al.* 2016. Nat Commun. 7:12073. [PubMed](#)
144. Yin X, *et al.* 2020. Cell Rep. 33:108278. [PubMed](#)
145. Xu W, *et al.* 2021. Immunity. 54(3):526-541.e7. [PubMed](#)
146. Sheppard S, *et al.* 2021. Cell Reports. 35(9):109210. [PubMed](#)
147. Di Pilato M, *et al.* 2021. Cell. 184(17):4512-4530.e22. [PubMed](#)
148. Borkner L, *et al.* 2017. J Immunol. 10.4049/jimmunol.1602115. [PubMed](#)
149. Hendrikx S *et al.* 2019. Cell reports. 26(5):1227-1241 . [PubMed](#)
150. Field CS, *et al.* 2020. Cell Metab. 31:422. [PubMed](#)
151. Ireland L, *et al.* 2020. Front Immunol. 11:297. [PubMed](#)
152. Van Den Eeckhout B, *et al.* 2020. NPJ Vaccines. 0.252777778. [PubMed](#)
153. Cohen MA, *et al.* 2020. Cell Stem Cell. 26(4):579-592. [PubMed](#)
154. Chao JL, *et al.* 2021. Cell Rep Med. 2:100399. [PubMed](#)
155. Sun Y, *et al.* 2020. J Immunol. 205:2649. [PubMed](#)
156. Zhang Z, *et al.* 2020. Nature. 579:415. [PubMed](#)
157. Le QV, *et al.* 2022. Bioact Mater. 15:160. [PubMed](#)
158. Kohn M, *et al.* 2021. Front Immunol. 626627:12. [PubMed](#)
159. Guo X, *et al.* 2020. J Cell Mol Med. . [PubMed](#)
160. Siolas D, *et al.* 2021. Cell Reports. 36(8):109578. [PubMed](#)
161. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. [PubMed](#)
162. Kunishita Y, *et al.* 2020. Front Immunol. 11:98. [PubMed](#)
163. Eckert EC, *et al.* 2020. Mol Ther Oncolytics. 0.710416667. [PubMed](#)
164. Parks CA, *et al.* 2019. Proc Natl Acad Sci U S A. 116:3136. [PubMed](#)
165. Säwen P *et al.* 2018. eLife. 7 pii: e41258. [PubMed](#)
166. White JP *et al.* 2018. Cell. 175(5):1198-1212 . [PubMed](#)
167. Sun Y, *et al.* 2022. iScience. 25:104846. [PubMed](#)
168. Barsoumian HB, *et al.* 2022. Cancers (Basel). 14:. [PubMed](#)
169. Teng F, *et al.* 2021. Cell Rep. 37:110051. [PubMed](#)
170. Chen YL, *et al.* 2022. Front Neurosci. 16:876582. [PubMed](#)
171. Wang J, *et al.* 2021. Am J Cancer Res. 11:2005. [PubMed](#)
172. RL M, *et al.* 2015. Proc Natl Acad Sci U S A. 112:6506-6514. [PubMed](#)
173. Gorman M, *et al.* 2016. J Virol. 90: 8212 - 8225. [PubMed](#)
174. Goc J, *et al.* 2021. Cell. . [PubMed](#)
175. Li A, *et al.* 2018. Cancer Lett. 431:54. [PubMed](#)
176. Caetano MS, *et al.* 2019. Clin Cancer Res. 25:7576. [PubMed](#)
177. Hu Y, *et al.* 2021. J Nanobiotechnology. 19:416. [PubMed](#)
178. Dai B, *et al.* 2021. Cell Reports Medicine. 2(8):100381. [PubMed](#)
179. Cortez MA, *et al.* 2020. Nat Commun. 3.819444444. [PubMed](#)
180. Xiang W, *et al.* 2020. Signal Transduct Target Ther. 0.374305556. [PubMed](#)
181. Harvey RE *et al.* 2017. Endocrinology. 158(7):2179-2189 . [PubMed](#)
182. Strattan E, *et al.* 2020. Frontiers in Immunology. 2.131944444. [PubMed](#)
183. Wolf Y, *et al.* 2019. Cell. 179:219. [PubMed](#)
184. Mohammed RN, *et al.* 2019. Sci Rep. 4.185416667. [PubMed](#)
185. Tan DQ, *et al.* 2019. Cell Rep. 26:2316. [PubMed](#)
186. Li CY, *et al.* 2022. Int J Mol Sci. 23:. [PubMed](#)
187. Chang MH, *et al.* 2021. Cell Rep. 37:109902. [PubMed](#)

RRID AB\_2075239 (BioLegend Cat. No. 100733)  
 AB\_2075238 (BioLegend Cat. No. 100734)

## Antigen Details

---

<b>Structure</b>	Ig superfamily, CD8 $\alpha$ chain, 34 kD
<b>Distribution</b>	Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells
<b>Function</b>	Co-receptor for TCR
<b>Ligand/Receptor</b>	MHC class I molecule

## Antigen References

1. Barclay A, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyka R. 1994. *Immunity* 1:243.
3. Ellmeier W, *et al.* 1999. *Annu. Rev. Immunol.* 17:523.

## Gene ID

[12525](#)


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD8a, Biotin anti-mouse CD8a, FITC anti-mouse CD8a, PE anti-mouse CD8a, PE/Cyanine5 anti-mouse CD8a, Purified anti-mouse CD8a, PE/Cyanine7 anti-mouse CD8a, APC/Cyanine7 anti-mouse CD8a, Alexa Fluor® 488 anti-mouse CD8a, Alexa Fluor® 647 anti-mouse CD8a, Pacific Blue™ anti-mouse CD8a, Alexa Fluor® 700 anti-mouse CD8a, PerCP/Cyanine5.5 anti-mouse CD8a, PerCP anti-mouse CD8a, Brilliant Violet 421™ anti-mouse CD8a, Brilliant Violet 570™ anti-mouse CD8a, Brilliant Violet 650™ anti-mouse CD8a, Brilliant Violet 605™ anti-mouse CD8a, Ultra-LEAF™ Purified anti-mouse CD8a, Brilliant Violet 711™ anti-mouse CD8a, Brilliant Violet 785™ anti-mouse CD8a, Brilliant Violet 510™ anti-mouse CD8a, Purified anti-mouse CD8a (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD8a, PE/Dazzle™ 594 anti-mouse CD8a, APC/Fire™ 750 anti-mouse CD8a, GolnVivo™ Purified anti-mouse CD8a, TotalSeq™-A0002 anti-mouse CD8a, Spark Blue™ 550 anti-mouse CD8a, Spark NIR™ 685 anti-mouse CD8a, TotalSeq™-C0002 anti-mouse CD8a, TotalSeq™-B0002 anti-mouse CD8a, Spark YG™ 570 anti-mouse CD8a, PE/Fire™ 640 anti-mouse CD8a, PE/Fire™ 700 anti-mouse CD8a, Spark Blue™ 574 anti-mouse CD8a Antibody, Spark Violet™ 423 anti-mouse CD8a Antibody, Spark UV™ 387 anti-mouse CD8a

## Product Data



C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587